Risk of subsequent non-germ cell cancer after treatment of germ cell cancer in 2006 Norwegian male patients

European Journal of Cancer Part A

Volumn 33, Issue 2, 1997, Pages 253-262

  Wanderås, E Hoff ^a,b   Fossa S D ^a   Tretli, S ^b  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

^b CANCER REGISTRY OF NORWAY   (Norway)

Author keywords

Chemotherapy; Germ cell neoplasms; Radiotherapy; Relative risk; Second cancer; Second sarcoma; Subsequent cancer; Testicular neoplasms; Treatment induced risk

Indexed keywords

CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN;

ADULT; ARTICLE; CANCER RISK; GERM CELL TUMOR; HUMAN; MAJOR CLINICAL STUDY; MALE; NORWAY; PRIORITY JOURNAL; SARCOMA; SECOND CANCER;

EID: 0342894831     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(96)00458-3     Document Type: Article

References (41)

1. Hanks GE, Peters T, Owen J. Seminoma of the testis: long-term beneficial and deleterious results of radiation. Int J Radiat Oncol Biol Phys 1992, 24, 913-919.
2. Hay JH, Duncan W, Kerr GR. Subsequent malignancies in patients irradiated for testicular tumours. Br J Radiat 1984, 57, 597-602.
3. Fosså SD, Langmark F, Aass N, Andersen A, Lothe R, Bslash c signrresen AL. Second non-germ cell malignancies after radiotherapy of testicular cancer with or without chemotherapy. Br J Cancer 1990, 61, 639-643.
4. Hellbardt A, Mirimanoff RO, Obradovic M, Mermillod B, Paunier JP. The risk of second cancer (SC) in patients treated for testicular seminoma. Int J Radiat Oncol Biol Phys 1990, 18, 1327-1331.
5. Dieckmann KP, Wegner HE, Krain J. Multiple primary neoplasms in patients with testicular germ cell tumor. Oncology 1994, 51, 450-458.
6. Horwich A, Bell J. Mortality and cancer incidence following radiotherapy for seminoma of the testis. Radiother Oncol 1994, 30, 193-198.
7. Kleinerman RA, Liebermann JV, Li FP. Second cancer following cancer of the male genital system in Connecticut, 1935-82. Natl Cancer Inst Monogr 1985, 68, 139-147.
8. Møller H, Mellemgaard A, Jacobsen GK, Pedersen D, Storm HH. Incidence of second primary cancer following testicular cancer. Eur J Cancer 1993, 29A, 672-676.
9. Van Leeuwen FE, Stiggelbout AM, van den Belt Dusebout AW, et al. Second cancer risk following testicular cancer: a follow-up study of 1,909 patients [see comments]. J Clin Oncol 1993, 11, 415-424.
10. Travis LB, Curtis RE, Hankey BF. Second malignancies after testicular cancer [letter]. J Clin Oncol 1995, 13, 533-534.
11. Peckham MJ, Barret A, McElwain TJ, Hendry WF. Combined management of malignant teratoma of the testis. Lancet 1979, 11, 267-270.
12. Fosså SD, Aass N, Kaalhus O. Radiotherapy for testicular seminoma stage I: treatment results and long-term post-irradiation morbidity in 365 patients. Int J Radiat Oncol Biol Phys 1989, 16, 383-388.
13. Klepp O, Klepp R, Hslash c signst H, Asbjslash c signrnsen G, Talle K, Stenwig AE. Combination chemotherapy of germ cell tumors of the testis with vincristine, adriamycin, cyclophosphamide, actinomycin D and medroxyprogesterone acetate. Cancer 1977, 40, 638-646.
14. Lewis CR, Fossa SD, Mead G, et al. BOP/VIP - a new platinum-intensive chemotherapy regimen for poor prognosis germ cell tumours. Ann Oncol 1991, 2, 203-211.
15. Cullen MH, Slenning SP, Parkinson MC, et al. Short course adjuvant chemotherapy in high risk stage I non-seminomatous germ cell tumours of the testis (NSGCTT): an MRC (UK) study report. Proc Am Soc Clin Oncol 1995, 14, 244 (Conference proceedings).
16. Kaplan EL, Meier P. Non-parametric estimation from incomplete observations. J Am Stat Assoc 1958, 53, 457-481.
17. Kaldor JM, Day NE, Band P, et al. Second malignancies following testicular cancer, ovarian cancer and Hodgkin's disease: an international collaborative study among cancer registries. Int J Cancer 1987, 39, 571-585.
18. de Vathaire F, Francois P, Hill C, et al. Role of radiotherapy and chemotherapy in the risk of second malignant neoplasms after cancer in childhood. Br J Cancer 1989, 59, 792-796.
19. Abrahamsen JF, Andersen A, Hannisdal E, et al. Second malignancies after treatment of Hodgkin's disease: the influence of treatment, follow-up time, and age [see comments]. J Clin Oncol 1993, 11, 255-261.
20. Pedersen Bjergaard J, Ersboll J, Hansen VL, et al. Carcinoma of the urinary bladder after treatment with cyclophosphamide for non-Hodgkin's lymphoma. N Engl J Med 1988, 318, 1028-1032.
21. Baker GL, Kahl LE, Zee BC, Stolzer BL, Agarwal AK, Medsger TA Jr. Malignancy following treatment of rheumatoid arthritis with cyclophosphamide. Long-term case-control follow-up study. Am J Med 1987, 83, 1-9.
22. Travis LB, Curtis RE, Glimelius B, et al. Bladder and kidney cancer following cyclophosphamide therapy for non-Hodgkin's lymphoma. J Natl Cancer Int 1995, 87, 524-530.
23. Petru E, Berger MR, Schmahl D. Long-term carcinogenicity of cyclophosphamide in two mouse strains with different spontaneous leukemia incidence. Cancer Lett 1989, 44, 221-226.
24. Dedrick RL, Morrison PF. Carcinogenic potency of alkylating agents in rodents and humans. Cancer Res 1992, 52, 2464-2467.
25. Shimizu Y, Kato H, Schull WJ. Studies of the mortality of Abomb survivors. 9. Mortality, 1950-1985: Part 2. Cancer mortality based on the recently revised doses (DS86). Radiat Res 1990, 121, 120-141.
26. Darby SC, Reeves G, Key T, Doll R, Stovall M. Mortality in a cohort of women given X-ray therapy for metropathia haemorrhagica. Int J Cancer 1994, 56, 793-801.
27. Weiss HA, Darby SC, Doll R. Cancer mortality following X-ray treatment for ankylosing spondylitis. Int J Cancer 1994, 59, 327-338.
28. Redman JR, Vugrin D, Arlin ZA, et al. Leukemia following treatment of germ cell tumors in men. J Clin Oncol 1984, 2, 1080-1087.
29. Pedersen-Bjergaard J, Daugaard G, Hansen SW, Philip P, Larsen SO, Rörth M. Increased risk of myelodysplasia and leukaemia after etoposide, cisplatin, and bleomycin for germ-cell tumours [see comments]. Lancet 1991, 338, 359-363.
30. Bajorin DF, Motzer RJ, Rodriguez E, Murphy B, Bosl GJ. Acute nonlymphocytic leukemia in germ cell tumor patients treated with etoposide-containing chemotherapy. J Natl Cancer Inst 1993, 85, 60-62.
31. Bokemeyer C, Schmoll HJ. Secondary neoplasms following treatment of malignant germ cell tumors. J Clin Oncol 1993, 11, 1703-1709.
32. Nichols CR, Breeden ES, Loehrer PJ, Williams SD, Einhorn LH. Secondary leukemia associated with a conventional dose of etoposide: review of serial germ cell tumor protocols. J Natl Cancer Inst 1993, 85, 36-40.
33. Boshoff C, Begent RH, Oliver RT, et al. Secondary tumours following etoposide containing therapy for germ cell cancer. Ann Oncol 1995, 6, 35-40.
34. Jacobsen GK, Mellemgaard A, Engelholm SA, Möller H. [Increased incidence of sarcoma in patients treated for seminoma] Oget incidens af sarkom hos patienter behandlet for seminom. Ugeskr Laeger 1994, 156, 809-812.
35. Laskin WB, Silverman TA, Enzinger FM. Postradiation soft tissue sarcomas. An analysis of 53 cases. Cancer 1988, 62, 2330-2340.
36. Ulbright TM, Loehrer PJ, Roth LM, Einhorn LH, Williams SD, Clark SA. The development of non-germ cell malignancies within germ cell tumors. A clinicopathologic study of 11 cases. Cancer 1984, 54, 1824-1833.
37. Naka N, Ohsawa M, Tomita Y, Kanno H, Uchida A, Aozasa K. Angiosarcoma in Japan. A review of 99 cases. Cancer 1995, 75, 989-996.
38. Sordillo PP, Chapham R, Hajdu SI, Magill GB, Golbey RB. Lymphangiosarcoma. Cancer 1981, 48, 1674-1679.
39. Falk H, Herbert J, Crowley S, et al. Epidemiology of hepatic angiosarcoma in the United States: 1964-1974. Environ Health Perspea 1981, 41, 107-113.
40. Ross RK, Coetzee GA, Reichardt J, Skinner E, Henderson BE. Does the Racial-Ethnic variation in prostate cancer risk have hormonal basis? Cancer 1995, 75, 1778-1782.
41. Fosså SD, Åbyholm T, Aakvaag A. Spermatogenesis and hormonal status after orchiectomy for cancer and before supplementary treatment. Eur Urol 1984, 10, 173-177.